Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan in HFrEF (PROVE-HF)
NCT02887183Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Started Oct 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02887183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02887183.